These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 32019315)
1. Metabolic syndrome, non-alcoholic fatty liver disease and hepatocarcinoma. Serradilla Martín M; Oliver Guillén JR; Palomares Cano A; Ramia Ángel JM Rev Esp Enferm Dig; 2020 Feb; 112(2):133-138. PubMed ID: 32019315 [TBL] [Abstract][Full Text] [Related]
2. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? Scalera A; Tarantino G World J Gastroenterol; 2014 Jul; 20(28):9217-28. PubMed ID: 25071314 [TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Dhamija E; Paul SB; Kedia S Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369 [TBL] [Abstract][Full Text] [Related]
6. [Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016]. Pár A; Pár G Orv Hetil; 2016 Jun; 157(25):987-94. PubMed ID: 27287838 [TBL] [Abstract][Full Text] [Related]
7. [Metabolic syndrome, non alcoholic hepatic steatopathy and hepatocellular carcinoma: so dangerous liaisons]. Rosmorduc O; Fartoux L Bull Acad Natl Med; 2014 Dec; 198(9):1653-63; discussion 1663-4. PubMed ID: 27356367 [TBL] [Abstract][Full Text] [Related]
8. Obesity as a cause of hepatocellular carcinoma. Kew MC Ann Hepatol; 2015; 14(3):299-303. PubMed ID: 25864208 [TBL] [Abstract][Full Text] [Related]
9. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697 [TBL] [Abstract][Full Text] [Related]
10. [Prevalence and harm of nonalcoholic fatty liver disease]. Shao YL; Fan JG Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):10-13. PubMed ID: 30685917 [TBL] [Abstract][Full Text] [Related]
11. Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort. van den Berg EH; Amini M; Schreuder TC; Dullaart RP; Faber KN; Alizadeh BZ; Blokzijl H PLoS One; 2017; 12(2):e0171502. PubMed ID: 28152105 [TBL] [Abstract][Full Text] [Related]
12. The relationship between pancreas steatosis and the risk of metabolic syndrome and insulin resistance in Chinese adolescents with concurrent obesity and non-alcoholic fatty liver disease. Chiyanika C; Chan DFY; Hui SCN; So HK; Deng M; Yeung DKW; Nelson EAS; Chu WCW Pediatr Obes; 2020 Sep; 15(9):e12653. PubMed ID: 32351030 [TBL] [Abstract][Full Text] [Related]
13. The epidemiology of non-alcoholic fatty liver disease. Bellentani S Liver Int; 2017 Jan; 37 Suppl 1():81-84. PubMed ID: 28052624 [TBL] [Abstract][Full Text] [Related]
19. Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease". Jamialahmadi O; Bianco C; Pelusi S; Romeo S; Valenti L J Hepatol; 2021 Jun; 74(6):1494-1496. PubMed ID: 33676949 [No Abstract] [Full Text] [Related]
20. Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance. Yang KC; Hung HF; Lu CW; Chang HH; Lee LT; Huang KC Sci Rep; 2016 Jun; 6():27034. PubMed ID: 27246655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]